Reply:
Massimo Primignani, Giovanni Barosi, Gaetano Bergamaschi, Umberto Gianelli, Federica Fabris, Raffaella Reati, Alessandra Dell'Era, Paolo Bucciarelli, Pier Mannuccio Mannucci – 26 February 2007
Can we ignore minimal hepatic encephalopathy any longer?
Asif M. Qadri, Ben O. Ogunwale, Kevin D. Mullen – 26 February 2007
Hepatocytes from embryonic stem cells: Prometheus revisited?
Christian Liedtke, Konrad L. Streetz – 26 February 2007
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer‐specific apoptosis within a therapeutic window
Ronald Koschny, Tom M. Ganten, Jaromir Sykora, Tobias L. Haas, Martin R. Sprick, Armin Kolb, Wolfgang Stremmel, Henning Walczak – 26 February 2007 – Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) represents a novel promising anticancer biotherapeutic. However, TRAIL‐resistant tumor cells require combinatorial regimens to sensitize tumor but not normal cells for TRAIL‐induced apoptosis.
Vaccine‐induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD‐1 and chronicity
Christine S. Rollier, Glaucia Paranhos‐Baccala, Ernst J. Verschoor, Babs E. Verstrepen, Joost A. R. Drexhage, Zahra Fagrouch, Jean‐Luc Berland, Florence Komurian‐Pradel, Blandine Duverger, Nourredine Himoudi, Caroline Staib, Marcus Meyr, Mike Whelan, Joseph A. Whelan, Victoria A. Adams, Esther Larrea, José I. Riezu, Juan José Lasarte, Birke Bartosch, Francois‐L. Cosset, Willy J. M. Spaan, Helmut M. Diepolder, Gerd R. Pape, Gerd Sutter, Genevieve Inchauspe, Jonathan L.
Reply:
Benjamin L. Shneider, Eve A. Roberts, Regino P. González‐Peralta – 26 February 2007
Testing for minimal hepatic encephalopathy in the United States: An AASLD survey
Jasmohan Singh Bajaj, Ashkan Etemadian, Muhammad Hafeezullah, Kia Saeian – 26 February 2007
Pioglitazone for patients with type 2 diabetes and nonalcoholic steatohepatitis
Janet King, Kris V. Kowdley – 26 February 2007
A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA‐negative primary biliary cirrhosis
Sabine Oertelt, Roman Rieger, Carlo Selmi, Pietro Invernizzi, Aftab A. Ansari, Ross L. Coppel, Mauro Podda, Patrick S.C. Leung, M. Eric Gershwin – 26 February 2007 – The antimitochondrial response in primary biliary cirrhosis (PBC) is the most highly directed and specific self‐reacting antibody in human immunopathology. Originally, antimitochondrial antibodies (AMAs) were detected by indirect immunofluorescence (IIF) and found in approximately 90% of well‐documented patients with PBC.
Combined GM‐CSF and IL‐12 gene therapy synergistically suppresses the growth of orthotopic liver tumors
Chun‐Jung Chang, Yi‐Hsiang Chen, Kai‐Wen Huang, Hao‐Wei Cheng, Suit‐Fong Chan, Kuo‐Feng Tai, Lih‐Hwa Hwang – 26 February 2007 – Immunotherapy is often effective only for small tumor burdens and, in many cases, is restricted to subcutaneous tumors. Here, we investigated the antitumor effects of combination therapy with GM‐CSF and IL‐12 on orthotopic liver tumors with intermediate or large tumor volumes, or on chemically‐induced multifocal liver tumors in animals.